Efeito do kexxtoner na cetose subclinica
Miniatura indisponível
Data
2015
Autores
Título da revista
ISSN da revista
Título do Volume
Editora
Resumo
A Monensina é uma molécula da família dos antibióticos ionóforos à muito utilizada
por todo o mundo na produção animal embora em 2005 tenha sido proibida a sua utilização
no espaço da Comunidade Europeia por ser considerado um promotor de crescimento. Porem,
em 2013, foi apresentado ao mercado português, uma nova forma farmacêutica da Elanco®, o
Kexxtone®, que tinha como base esta mesma molécula e como finalidade o uso profilático
contra a cetose.
O presente estudo teve como objetivos avaliar a eficácia do Kexxtone® na prevenção
da cetose subclínica, assim como a sua influência na prevalência de patologias no período do
pós-parto. Foi ainda avaliado o seu efeito na involução uterina.
O estudo decorreu entre Março de 2014 e Janeiro de 2015 tendo sido incluídos 120
animais e realizadas 1440 observações numa exploração na Estremadura. Para selecionar os
animais de risco com uma condição corporal elevada foi medida a espessura da gordura
subcutânea por ultrassonografia. Foi utilizado o Keto-Test® para avaliação da cetose
subclínica
Com este estudo foi possível concluir que o Kexxtone® é eficaz na prevenção de
cetose subclínica e deslocamentos de abomaso apresentando ainda um efeito positivo na
involução uterina.
The Monensin is a molecule of the ionophore antibiotics’s family often used worldwide in animal production but in 2005 this molecule has been banned for use in the European Community once it has been considered a growth promoter. In 2013, was presented to the Portuguese market, a new pharmaceutical form of Elanco®, the Kexxtone®, which was based on the same molecule and as purpose to prophylactic use against ketosis. The aim of this study is the evaluation of Kexxtone®’s effectiveness in preventing subclinical ketosis, as well as its influence on the prevalence of post partum’s diseases. The effect of this product on uterine involution was evaluated. The study took place between March 2014 and January 2015 which were included 120 animals and 1440 observations have been made on a single farm in Estremadura. To select risk animals with a high body condition score was measured subcutaneous fat thickness by ultrasound. Keto-Test® was used for evaluation of subclinical ketosis. With this study it was concluded that the Kexxtone® is effective in the prevention of subclinical ketosis and abomasal displacements and still has a positive effect on uterine involution.
The Monensin is a molecule of the ionophore antibiotics’s family often used worldwide in animal production but in 2005 this molecule has been banned for use in the European Community once it has been considered a growth promoter. In 2013, was presented to the Portuguese market, a new pharmaceutical form of Elanco®, the Kexxtone®, which was based on the same molecule and as purpose to prophylactic use against ketosis. The aim of this study is the evaluation of Kexxtone®’s effectiveness in preventing subclinical ketosis, as well as its influence on the prevalence of post partum’s diseases. The effect of this product on uterine involution was evaluated. The study took place between March 2014 and January 2015 which were included 120 animals and 1440 observations have been made on a single farm in Estremadura. To select risk animals with a high body condition score was measured subcutaneous fat thickness by ultrasound. Keto-Test® was used for evaluation of subclinical ketosis. With this study it was concluded that the Kexxtone® is effective in the prevention of subclinical ketosis and abomasal displacements and still has a positive effect on uterine involution.
Descrição
Orientação: João Cannas da Silva ; Co-orientação: João Paisana
Palavras-chave
VETERINÁRIA, MESTRADO INTEGRADO EM MEDICINA VETERINÁRIA, MONENSINA, MEDICAMENTOS, MONENSIN, DOENÇAS METABÓLICAS, METABOLIC DISEASES, PUERPÉRIO, PUERPERIUM, MEDICINA VETERINÁRIA, VETERINARY MEDICINE, DRUGS